Blumkin Lubov, Leshinsky-Silver Esther, Zerem Ayelet, Yosovich Keren, Lerman-Sagie Tally, Lev Dorit
Metabolic Neurogenetic Service, Wolfson Medical Center, Holon, Israel.
JIMD Rep. 2014;12:103-7. doi: 10.1007/8904_2013_251. Epub 2013 Sep 19.
We describe a highly variable clinical presentation of cerebellar ataxia in two sisters. The younger sister demonstrates early onset rapidly progressive cerebellar ataxia accompanied by motor and nonmotor cerebellar features, as well as cognitive decline and psychiatric problems. Mitochondrial respiratory chain enzyme analysis in muscle showed a decrease in complex I + III. Progressive cerebellar atrophy was demonstrated on serial brain MR imaging. Coenzyme Q10 (CoQ10) supplementation, started at the age of 5 years, led to a significant improvement in motor and cognitive abilities with partial amelioration of the cerebellar signs. Discontinuation of this treatment resulted in worsening of the ataxia, cognitive decline, and severe depression.The older sister, who is 32 years old, has nonprogressive dysarthria and clumsiness from the age of 10 years and MRI reveals cerebellar atrophy.Exome sequencing identified compound heterozygosity for a known (p. Thr584delACC (c.1750_1752delACC)) and a novel (p.P502R) mutation in the ACDK3 gene.
Patients with primary CoQ10 deficiency due to ADCK3 mutations can demonstrate a wide spectrum of clinical presentations even in the same family. It is difficult to diagnose CoQ10 deficiency based solely on the clinical presentation.Exome sequencing can provide the molecular diagnosis but since it is expensive and not readily available, we recommend a trial of CoQ10 treatment in patients with ataxia and cerebellar atrophy even before confirmation of the molecular diagnosis.
我们描述了两姐妹小脑共济失调的高度可变临床表现。妹妹表现为早发性快速进展性小脑共济失调,伴有运动和非运动性小脑特征,以及认知能力下降和精神问题。肌肉线粒体呼吸链酶分析显示复合体I + III减少。连续脑部磁共振成像显示进行性小脑萎缩。5岁开始补充辅酶Q10(CoQ10),使运动和认知能力有显著改善,小脑体征部分缓解。停止这种治疗导致共济失调恶化、认知能力下降和严重抑郁。32岁的姐姐自10岁起有非进行性构音障碍和笨拙,磁共振成像显示小脑萎缩。外显子组测序确定在ACDK3基因中有一个已知突变(p.Thr584delACC(c.1750_1752delACC))和一个新突变(p.P502R)的复合杂合性。
由于ACDK3突变导致原发性CoQ10缺乏的患者即使在同一家族中也可表现出广泛的临床症状。仅根据临床表现很难诊断CoQ10缺乏。外显子组测序可提供分子诊断,但由于其昂贵且不易获得,我们建议即使在分子诊断确认之前,对患有共济失调和小脑萎缩的患者进行CoQ10治疗试验。